These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33288765)

  • 21. Accurate quantification of copy-number aberrations and whole-genome duplications in multi-sample tumor sequencing data.
    Zaccaria S; Raphael BJ
    Nat Commun; 2020 Sep; 11(1):4301. PubMed ID: 32879317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data.
    Abécassis J; Hamy AS; Laurent C; Sadacca B; Bonsang-Kitzis H; Reyal F; Vert JP
    PLoS One; 2019; 14(11):e0224143. PubMed ID: 31697689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CloneCNA: detecting subclonal somatic copy number alterations in heterogeneous tumor samples from whole-exome sequencing data.
    Yu Z; Li A; Wang M
    BMC Bioinformatics; 2016 Aug; 17():310. PubMed ID: 27538789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression.
    Espiritu SMG; Liu LY; Rubanova Y; Bhandari V; Holgersen EM; Szyca LM; Fox NS; Chua MLK; Yamaguchi TN; Heisler LE; Livingstone J; Wintersinger J; Yousif F; Lalonde E; Rouette A; Salcedo A; Houlahan KE; Li CH; Huang V; Fraser M; van der Kwast T; Morris QD; Bristow RG; Boutros PC
    Cell; 2018 May; 173(4):1003-1013.e15. PubMed ID: 29681457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma.
    Farmanbar A; Firouzi S; Makałowski W; Kneller R; Iwanaga M; Utsunomiya A; Nakai K; Watanabe T
    Neoplasia; 2018 Sep; 20(9):883-893. PubMed ID: 30032036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
    VanderWeele DJ; Finney R; Katayama K; Gillard M; Paner G; Imoto S; Yamaguchi R; Wheeler D; Lack J; Cam M; Pontier A; Nguyen YTM; Maejima K; Sasaki-Oku A; Nakano K; Tanaka H; Vander Griend D; Kubo M; Ratain MJ; Miyano S; Nakagawa H
    Eur Urol Focus; 2019 May; 5(3):416-424. PubMed ID: 29398457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CONIPHER: a computational framework for scalable phylogenetic reconstruction with error correction.
    Grigoriadis K; Huebner A; Bunkum A; Colliver E; Frankell AM; Hill MS; Thol K; Birkbak NJ; Swanton C; Zaccaria S; McGranahan N
    Nat Protoc; 2024 Jan; 19(1):159-183. PubMed ID: 38017136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins.
    Lindberg J; Klevebring D; Liu W; Neiman M; Xu J; Wiklund P; Wiklund F; Mills IG; Egevad L; Grönberg H
    Eur Urol; 2013 Feb; 63(2):347-53. PubMed ID: 22502944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How many samples are needed to infer truly clonal mutations from heterogenous tumours?
    Opasic L; Zhou D; Werner B; Dingli D; Traulsen A
    BMC Cancer; 2019 Apr; 19(1):403. PubMed ID: 31035962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling and correct the GC bias of tumor and normal WGS data for SCNA based tumor subclonal population inferring.
    Chu Y; Teng M; Wang Y
    BMC Bioinformatics; 2018 Apr; 19(Suppl 5):112. PubMed ID: 29671389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The MOBSTER R package for tumour subclonal deconvolution from bulk DNA whole-genome sequencing data.
    Caravagna G; Sanguinetti G; Graham TA; Sottoriva A
    BMC Bioinformatics; 2020 Nov; 21(1):531. PubMed ID: 33203356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer.
    Leong TL; Gayevskiy V; Steinfort DP; De Massy MR; Gonzalez-Rajal A; Marini KD; Stone E; Chin V; Havryk A; Plit M; Irving LB; Jennings BR; McCloy RA; Jayasekara WSN; Alamgeer M; Boolell V; Field A; Russell PA; Kumar B; Gough DJ; Szczepny A; Ganju V; Rossello FJ; Cain JE; Papenfuss AT; Asselin-Labat ML; Cowley MJ; Watkins DN
    Oncogene; 2019 Mar; 38(10):1661-1675. PubMed ID: 30348992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.
    Hong MK; Macintyre G; Wedge DC; Van Loo P; Patel K; Lunke S; Alexandrov LB; Sloggett C; Cmero M; Marass F; Tsui D; Mangiola S; Lonie A; Naeem H; Sapre N; Phal PM; Kurganovs N; Chin X; Kerger M; Warren AY; Neal D; Gnanapragasam V; Rosenfeld N; Pedersen JS; Ryan A; Haviv I; Costello AJ; Corcoran NM; Hovens CM
    Nat Commun; 2015 Apr; 6():6605. PubMed ID: 25827447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CloneSig can jointly infer intra-tumor heterogeneity and mutational signature activity in bulk tumor sequencing data.
    Abécassis J; Reyal F; Vert JP
    Nat Commun; 2021 Sep; 12(1):5352. PubMed ID: 34504064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SubClonal Hierarchy Inference from Somatic Mutations: Automatic Reconstruction of Cancer Evolutionary Trees from Multi-region Next Generation Sequencing.
    Niknafs N; Beleva-Guthrie V; Naiman DQ; Karchin R
    PLoS Comput Biol; 2015 Oct; 11(10):e1004416. PubMed ID: 26436540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity.
    Kim TM; Jung SH; An CH; Lee SH; Baek IP; Kim MS; Park SW; Rhee JK; Lee SH; Chung YJ
    Clin Cancer Res; 2015 Oct; 21(19):4461-72. PubMed ID: 25979483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data.
    Fan Y; Xi L; Hughes DS; Zhang J; Zhang J; Futreal PA; Wheeler DA; Wang W
    Genome Biol; 2016 Aug; 17(1):178. PubMed ID: 27557938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple Origin and Tumor Heterogeneity of Prostatic Ductal Adenocarcinoma in the Han Chinese Population.
    Zhang W; Su F; Wang M; Hou H; Liu M; Liu D; Liu H
    Genet Test Mol Biomarkers; 2021 Nov; 25(11):727-732. PubMed ID: 34788144
    [No Abstract]   [Full Text] [Related]  

  • 39. Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies.
    Parisi F; Ariyan S; Narayan D; Bacchiocchi A; Hoyt K; Cheng E; Xu F; Li P; Halaban R; Kluger Y
    BMC Genomics; 2011 May; 12():230. PubMed ID: 21569352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic and phenotypic heterogeneity in prostate cancer.
    Haffner MC; Zwart W; Roudier MP; True LD; Nelson WG; Epstein JI; De Marzo AM; Nelson PS; Yegnasubramanian S
    Nat Rev Urol; 2021 Feb; 18(2):79-92. PubMed ID: 33328650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.